Sectors
DNLI
Denali Therapeutics Inc.
19.72
2 x 14.39
2 x 25.28
bid
ask
-
0.41
2.04%
2 @ 07:39 PM
19.98 +0.26 (1.34%)
| Ytd | 19.44% | |
| 1y | 49.62% |
19.63
day range
20.16
12.75
52 week range
27.21
| Open | 20.07 | Prev Close | 20.13 | Low | 19.63 | High | 20.16 | Mkt Cap | 3.15B |
| Vol | 2.96M | Avg Vol | 1.56M | EPS | -2.84 | P/E | N/A | Forward P/E | -8.15 |
| Beta | 1.00 | Short Ratio | 13.76 | Inst. Own | 101.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 23.64 | 200-d Avg | 20.95 | 1yr Est | 36.06 |
| Income Statement | |||
| Total Revenue | 3.60M | ||
| Revenues (USD) | 3.60M | ||
| Cost of Revenue | 93.00K | ||
| Gross Profit | 3.51M | ||
| Operating Expenses | 134.05M | ||
| Research and Development Expense | 97.02M | ||
| Selling, General and Administrative Expense | 36.28M | ||
| Operating Income | -130.54M | ||
| Net Income | -127.55M | ||
| Net Income Common Stock | -127.55M | ||
| Net Income Common Stock (USD) | -127.55M | ||
| Consolidated Income | -127.55M | ||
| Earnings per Basic Share | -0.68 | ||
| Earnings per Basic Share (USD) | -0.68 | ||
| Earnings per Diluted Share | -0.68 | ||
| Earning Before Interest & Taxes (EBIT) | -127.55M | ||
| Earning Before Interest & Taxes (USD) | -127.55M | ||
| Weighted Average Shares | 187.31M | ||
| Weighted Average Shares Diluted | 187.31M | ||
| Balance Sheet | |||
| Cash and Equivalents | 201.53M | ||
| Cash and Equivalents (USD) | 201.53M | ||
| Investments | 738.48M | ||
| Investments Current | 508.94M | ||
| Investments Non-Current | 229.53M | ||
| Trade and Non-Trade Receivables | 3.93M | ||
| Current Assets | 753.93M | ||
| Property, Plant & Equipment Net | 113.42M | ||
| Total Assets | 1.16B | ||
| Total Debt | 232.69M | ||
| Current Liabilities | 90.08M | ||
| Debt Non-Current | 232.69M | ||
| Total Liabilities | 322.78M | ||
| Accumulated Retained Earnings (Deficit) | -2.31B | ||
| Accumulated Other Comprehensive Income | -1.97M | ||
| Shareholders Equity | 835.18M | ||
| Shareholders Equity (USD) | 835.18M | ||
| Assets Non-Current | 404.03M | ||
| Total Debt (USD) | 232.69M | ||
| Goodwill and Intangible Assets | 35.25M | ||
| Inventory | 4.14M | ||
| Liabilities Non-Current | 232.69M | ||
| Trade and Non-Trade Payables | 11.81M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 4.48M | ||
| Net Cash Flow from Financing | 14.98M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -186.10M | ||
| Capital Expenditure | -805.00K | ||
| Issuance (Purchase) of Equity Shares | 15.01M | ||
| Issuance (Repayment) of Debt Securities | -21.00K | ||
| Net Cash Flow from Investing | -104.08M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -74.47M | ||
| Net Cash Flow from Operations | -97.00M | ||
| Share Based Compensation | 22.92M | ||